Mark Rothera, Chief Commercial Officer at PTC THERAPEUTICS, INC. (PTCT), sold 16,000 shares at $44.92 ($714K) on 2014-09-25, disclosed to the SEC on 2014-09-26.
Scheduled sale ($714k) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.88 | 2,000 | $86K | 12.0% |
| 2 | $43.86 | 900 | $39K | 5.5% |
| 3 | $44.15 | 7,100 | $313K | 43.9% |
| 4 | $44.92 | 3,000 | $135K | 18.9% |
| 5 | $46.90 | 3,000 | $141K | 19.7% |
| Total | $44.63 avg | 16,000 |
| $714K |
| 100% |
| Filing → |
| PTCT | SELL | 2015-03-18 | $820K | — | Filing → |
| PTCT | SELL | 2015-03-13 | $23K | — | Filing → |
| PTCT | SELL | 2015-02-25 | $2.4M | — | Filing → |